Omega Funds
Venture Capital
Active
Boston, United States
138
69M
100
6.90
22
0.28
48
- Stages of investment
- Areas of investment
Summary
The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Omega Funds performs on 7 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2017.
Besides them, we counted 3 critical employees of this fund in our database.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Intarcia Therapeutics, Gossamer Bio, Beam Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Biotechnology, Medical.
The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Omega Funds, startups are often financed by Polaris Partners, Flagship Pioneering, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Abingworth, The Baupost Group. In the next rounds fund is usually obtained by Polaris Partners, Atlas Venture, The Baupost Group.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 650000000
- Fund raised date
- 2021-12-17
Analytics
- Total investments
- 138
- Lead investments
- 22
- Exits
- 48
- Rounds per year
- 6.90
- Follow on index
- 0.28
- Investments by industry
- Biotechnology (108)
- Health Care (60)
- Therapeutics (51)
- Pharmaceutical (43)
- Medical (40) Show 57 more
- Investments by region
-
- United States (99)
- Switzerland (8)
- United Kingdom (5)
- Belgium (4)
- Norway (2) Show 7 more
- Peak activity year
- 2021
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 66M
- Group Appearance index
- 0.86
- Avg. company exit year
- 9
- Avg. multiplicator
- 1.30
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Marea Therapeutics | 18 Jun 2024 | Early Stage Venture | 190M | United States, California, San Francisco | |
| SoniVie | 09 Jan 2023 | Health Care, Health Diagnostics, Medical | Late Stage Venture | 60M | HaMerkaz, Rosh Ha'ayin, Israel |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.